Integrated BioPharma, Inc. filings document formal disclosures for a Delaware operating company whose public reports are tied to vitamins, nutritional supplements, herbal products and contract manufacturing. Recent Form 8-K filings furnish quarterly and fiscal-year results under Item 2.02, including press-release exhibits covering revenue, operating results and per-share data.
The filing record also includes material-event reports on credit-line arrangements and related-party lease matters involving the wholly owned subsidiary Manhattan Drug Company, as well as definitive proxy materials and annual meeting voting results covering director elections, executive-compensation votes, stockholder voting matters and governance procedures. Cover-page disclosures identify no securities registered on a national exchange under Section 12(b).
Integrated BioPharma, Inc. reported weaker results for the quarter ended March 31, 2026, with revenue of $10.1 million versus $13.9 million a year earlier, a 27.3% decline. The company swung from operating income of about $0.7 million to an operating loss of about $1.1 million, and from net income of about $0.6 million to a net loss of about $0.8 million, or $(0.03) per diluted share.
For the nine months ended March 31, 2026, revenue was $34.1 million compared to $40.2 million, down 15.2%, with a net loss of about $1.5 million versus net income of about $1.0 million a year earlier. Management noted that revenue from the two largest customers in the Contract Manufacturing Segment represented about 90% of total revenue in the 2026 period, up from 83% in 2025, underscoring significant customer concentration.
Integrated BioPharma, Inc. reported weaker results for the quarter and nine months ended March 31, 2026, driven by lower volumes and margin pressure. Net sales for the nine-month period fell to $34,076 from $40,178, a 15.2% decline, with Contract Manufacturing and Other Business Lines both down.
The company swung to a nine‑month operating loss of $1,836 from operating income of $1,431, and posted a net loss of $1,476 versus prior‑year net income of $986. For the March quarter, sales declined 27.5% to $10,107, producing a gross loss and net loss of $837.
Customer concentration remains high: two Contract Manufacturing customers accounted for about 90% of consolidated net sales, led by Life Extension and Herbalife. Despite the downturn, cash improved to $5,826 and working capital was about $12,447, supported by an undrawn revolving credit facility of roughly $4,500. Management highlights inflation, tariffs and labor costs as ongoing margin headwinds.
Integrated BioPharma Inc. saw a long‑standing shareholder group led by the late Carl DeSantis, CD Financial, LLC and CDS Group Holdings, L.L.C. report that it no longer beneficially owns any common stock. The filing states the group’s holdings fell to 0 shares, or 0.0% of the class.
Following DeSantis’s death, all of the group’s shares were transferred on March 24, March 30 and April 15, 2026 to CDDS 2.0, LLC, a Florida company controlled by Damon DeSantis. As a result, CDDS 2.0, LLC directly, and Damon DeSantis indirectly, now beneficially own more than five percent of Integrated BioPharma’s common stock.
Integrated BioPharma Inc. received an updated ownership report showing concentrated control of its common stock. CDDS 2.0, LLC now holds 12,733,058 shares, about 41.0% of the company’s 31,059,610 outstanding shares as of April 15, 2026. Damon DeSantis is deemed to beneficially own 12,920,558 shares, or 41.3%, through CDDS and 187,500 presently exercisable stock options held directly. These positions arose from internal transfers from CD Financial, LLC, the Carl DeSantis Revocable Trust, and the Estate of Carl DeSantis to CDDS for no cash consideration. The reporting group states it currently has no plans involving mergers, asset sales, control changes, or other actions listed in Item 4, while reserving the right to change its intentions.
INTEGRATED BIOPHARMA INC director William H. Milmoe reported bona fide gifts of 11,201,964 shares of Common Stock. The transactions were coded as gifts at $0.0000 per share, indicating non-cash transfers.
The filing notes that 8,966,547 shares were transferred from CD Financial, LLC to CDDS 2.0, LLC, a Florida LLC controlled by Damon DeSantis, and 2,235,417 shares were transferred from the Carl DeSantis Revocable Trust to the same LLC. Following these transfers, associated indirect holdings total 2,374,084 shares and Milmoe directly owns 138,667 shares.
INTEGRATED BIOPHARMA INC director William H. Milmoe reported large stock gifts involving entities he is associated with. On April 15, 2026, entities linked to him made bona fide gifts totaling 11,201,964 shares of Common Stock at a stated price of $0.00 per share.
One gift transferred 8,966,547 shares from CD Financial, LLC to CDDS 2.0, LLC, a Florida LLC controlled by Damon DeSantis. Another transferred 2,235,417 shares from the Carl DeSantis Revocable Trust to the same CDDS 2.0, LLC. After these gifts, Milmoe’s reported holdings were 2,374,084 shares indirectly and 138,667 shares directly of Integrated BioPharma Common Stock.
INTEGRATED BIOPHARMA INC major shareholder Carl DeSantis reported estate-related gift transfers of 11,201,964 shares of Common Stock. Two bona fide gifts on April 15, 2026 disposed of 8,966,547 shares held by CD Financial, LLC and 2,235,417 shares held by the Carl DeSantis Revocable Trust.
According to the footnotes, both blocks were transferred to CDDS 2.0, LLC, a Florida limited liability company controlled by Damon DeSantis. The reporting person is noted as deceased, and these are indirect holdings. After the second transfer, the filing shows 0 shares of Common Stock indirectly owned.
Integrated BioPharma director and 10% owner Damon DeSantis reported two bona fide gift transfers of Common Stock involving related entities. The filing shows gifts of 8,966,547 and 2,235,417 shares, for a total of 11,201,964 shares, at a stated price of $0 per share.
According to the footnotes, these shares were transferred from CD Financial, LLC and the Carl DeSantis Revocable Trust to CDDS 2.0, LLC, a Florida limited liability company controlled by DeSantis. After these transfers, DeSantis indirectly holds 12,733,058 shares of Integrated BioPharma Common Stock through CDDS 2.0, LLC.
Integrated BioPharma, Inc. reported that PNC Bank extended the expiration date of its line of credit, documented in an April 15, 2025 promissory note, from April 15, 2026 to July 14, 2026. The extension, which also covers subsidiary Manhattan Drug Company, Inc., becomes effective on April 16, 2026.
INTEGRATED BIOPHARMA INC insider reporting reflects non-market gifts of Common Stock by entities associated with the late Carl DeSantis. CD Financial, LLC transferred 1,356,293 shares and the Carl DeSantis Revocable Trust transferred 7,392 shares to CDDS 2.0, LLC, a Florida LLC controlled by Damon DeSantis. After these bona fide gifts, a total of 11,366,673 shares of Common Stock remain indirectly held through CD Financial, LLC, the revocable trust and the Estate of Carl DeSantis.